Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Refractory Takayasu Arteritis
NCT06662721Phase 2Completed
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in Takayasu arteritis (TAK). Primary endpoint: Patients achieving complete remission and partial remission at Week 24. Started Apr 2023; status: completed.
02
Drugs
baricitinib
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT06662721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662721.